Aurinia Pharmaceuticals Inc (AUPH)

[moosedogger]

LLY drug doesn't seem impressive:

"Results from the trial, which led to the FDA’s decision, showed that more patients receiving the 4 mg baricitinib dose were clear of arthritis or rash at 24 weeks — 67%, compared with 58% of those on 2 mg baricitinib or 53% of those receiving a placebo.

However, patients receiving the active treatment were also more likely to experience side effects — 71% on the 2 mg dose and 73% on the 4 mg dose — compared with 65% of those on a placebo. The rate of serious adverse events was also two times higher among baricitinib-treated patients."

https://lupusnewstoday.com/2018/12/21/fda-gives-baricitinib-fast-track-status/

LLY should seriously consider buying VCS